This agreement provides a clear, multi-year revenue stream from plasma sales, validating Kamada's vertical-integration strategy and supporting its FY2026 guidance. Traders should monitor Q4 2026 earnings for initial commercial sales under this agreement and any updates on the ramp-up of the plasma collection centers to full capacity.
Price Chart
Executive Summary
Kamada announced a three-year agreement to supply normal source plasma from its Texas collection centers to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue over three years. Initial commercial sales are expected in Q4 2026, and this agreement validates the company's investment in its U.S. plasma collection operations, supporting its vertical-integration strategy and multi-year revenue growth objectives. The agreement is included in the company's current annual guidance, which projects total revenues of $200-$205 million and adjusted EBITDA of $50-$53 million for fiscal year 2026.
Key Facts
- Kamada entered a three-year agreement to supply normal source plasma to a leading biopharmaceutical company.
- The agreement is expected to generate approximately $50 million in revenue over three years.
- Initial commercial sales are expected to be recorded in Q4 2026.
- Plasma will be sourced from Kamada's FDA-approved collection centers in Houston and San Antonio, Texas.
- Each center supports a planned capacity of approximately 50,000 liters per year at full capacity.
- The agreement is included in Kamada's current annual guidance of $200-$205 million in total revenues and $50-$53 million in adjusted EBITDA for fiscal year 2026.
- Kamada had anticipated the commencement of plasma sales by year-end 2026 when issuing its full-year revenue forecast.
Financial Impact
Approximately $50 million in revenue over three years from the supply agreement, included in the company's current annual guidance of $200-$205 million total revenue and $50-$53 million adjusted EBITDA for FY2026.
Risk Factors
- Operational ramp-up and efficiency of the plasma collection centers may not meet planned capacity of 50,000 liters per year per center.
- The agreement is with an undisclosed counterparty, introducing counterparty risk.
- Geopolitical risks from conflicts in the Middle East and potential tariffs could impact operations and profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079393 |
| Document: ea029849801ex99-1.htm | 0001213900-26-079393 |
| Document: 0001213900-26-079393-index-headers.html | 0001213900-26-079393 |
| Document: 0001213900-26-079393-index.html | 0001213900-26-079393 |
| Document: 0001213900-26-079393.txt | 0001213900-26-079393 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | EFFECT | $8.19 $8.77 | ▲ +7.08% | ▲ +4.52% | $8.20 (+0.12%) |
Sep 10, 2026 22d ago | 6-K | $7.99 $8.67 | ▲ +8.51% | ▲ +9.01% | $8.20 (+2.63%) |
Sep 3, 2026 29d ago | Press Release | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Sep 3, 2026 29d ago | 6-K | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Aug 17, 2026 6w ago | 6-K / PRESS-RELEASE | $7.76 $8.43 | ▲ +8.63% | ▲ +9.82% | $8.20 (+5.67%) |
Aug 12, 2026 7w ago | 6-K | $6.88 $7.89 | ▲ +14.68% | ▲ +15.12% | $8.20 (+19.19%) |
Aug 5, 2026 8w ago | 6-K | $7.14 $7.26 | ▲ +1.68% | ▲ +0.47% | $8.20 (+14.85%) |
Aug 5, 2026 8w ago | 6-K | $7.18 $6.88 | ▼ −4.18% | ▼ −4.53% | $8.20 (+14.21%) |
Jul 20, 2026 10w ago | 6-K | $7.09 $7.06 | ▼ −0.42% | ▲ +0.00% | $8.20 (+15.66%) |
Jul 13, 2026 11w ago | 6-K | $7.17 $7.05 | ▼ −1.67% | ▼ −0.89% | $8.20 (+14.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access